The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer

Modern Pathology

Volumn 25, Issue 8, 2012, Pages 1106-1116

  Woolston, Caroline M ^a   Zhang, Lei ^a   Storr, Sarah J ^a   Al Attar, Ahmad ^b   Shehata, Mohamed ^b   Ellis, Ian O ^c   Chan, Stephen Y ^b   Martin, Stewart G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

anthracycline; breast cancer; chemotherapy; glutathione; redox; thioredoxin interacting protein

Indexed keywords

ANTHRACYCLINE; CATALASE; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GLUTATHIONE TRANSFERASE ALPHA; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; MANGANESE SUPEROXIDE DISMUTASE; THIOREDOXIN; THIOREDOXIN INTERACTING PROTEIN; THIOREDOXIN REDUCTASE;

ADULT; ADVANCED CANCER; AGED; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DISTANT METASTASIS FREE SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; LOCALLY ADVANCED BREAST CANCER; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BIOPSY, LARGE-CORE NEEDLE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; ENZYMES; FEMALE; GREAT BRITAIN; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; OXIDATION-REDUCTION; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84864548167     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.60     Document Type: Review

References (33)

1. Muller I, Niethammer D, Bruchelt G. Anthracyclinederived chemotherapeutics in apoptosis and free radical cytotoxicity (review). Int J Mol Med 1998;1: 491-494.
2. Ravid A, Rocker D, Machlenkin A, et al. 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res 1999;59:862-867.
3. Pennington JD, Wang TJ, Nguyen P, et al. Redoxsensitive signalling factors as a novel molecular targets for cancer therapy. Drug Resist Updat 2005;8:322-330.
4. Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44-84.
5. Woolston CM, Deen S, Al-Attar A, et al. Redox protein expression predicts progression-free and overall survival in ovarian cancer patients treated by platinum-based chemotherapy. Free Radic Biol Med 2010; 49:1263-1272.
6. Woolston CM, Al-Attar A, Storr SJ, et al. Redox protein expression predicts radiotherapeutic response in earlystage invasive breast cancer patients. Int J Radiat Oncol Biol Phys 2011;79:1532-1540.
7. Toyokuni S, Okamoto K, Yodoi J, et al. Persistent oxidative stress in cancer. FEBS Lett 1995;358:1-3.
8. Behrend L, Henderson G, Zwacka RM. Reactive oxygen species in oncogenic transformation. Biochem Soc Trans 2003;31:1441-1444.
9. Mcshane LM, Altman DG, SauerbreiW, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 2006;100:229-235.
10. Park JO, Lee SI, Song SY, et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 2003;33:533-537.
11. Chevallier B, Roche H, Olivier JP, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993;16:16223-16228.
12. Ring AE, Smith IE, Ashley S, et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. B J Cancer 2004;91:2012-2017.
13. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-469.
14. Forrester LM, Hayes JD, Millis R, et al. Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue. Carcinogenesis 1990;11:2163-2170.
15. Alpert LC, Schecter RL, Berry DA, et al. Relation of glutathione S-transferase a and m isoforms to response to therapy in human breast cancer. Clin Cancer Res 1997;3:661-667.
16. Howie AF, Miller WR, Hawkins RA, et al. Expression of glutathione S-transferase B1, B2, Mu and Pi in breast cancers and their relationship to oestrogen receptor status. Br J Cancer 1989;60:834-837.
17. Montano MM, Deng H, Liu M, et al. Transcriptional regulation by the estrogen receptor of antioxidative stress enzymes and its functional implications. Oncogene 2004;23:2442-2453.
18. Moscow JA, Townsend AJ, Goldsmith ME, et al. Isolation of the human anionic glutathione S-transferase cDNA and the relation of its gene expression to estrogen-receptor content in primary breast cancer. Proc Natl Acad Sci USA 1988;85:6518-6522.
19. Nakanishi Y, Kawasaki M, Bai F, et al. Expression of p53 and glutathione S-transferase-pi relates to clinical drug resistance in non-small cell lung cancer. Oncology 1999;57:318-323.
20. Mayr D, Pannekamp U, Baretton GB, et al. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas. Pathol Res Pract 2000;196:469-475.
21. Gilbert L, Elwood LJ, Merino M, et al. A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J Clin Oncol 1993;11:49-58.
22. Huang J, Tan P-H, Thiyagarajan J, et al. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod Pathol 2003;16:558-565.
23. Arun BK, Granville LA, Yin G, et al. Glutathiones-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. Cancer Invest 2010;28:554-559.
24. Moureau-Zabotto L, Ricci S, Lefranc JP, et al. Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br J Cancer 2006;27:473-480.
25. Ravi D, Muniyappa H, Das KC. Endogenous thioredoxin is required for redox cycling of anthracyclines and p53-dependent apoptosis in cancer cells. J Biol Chem 2005;280:40084-40096.
26. Cadenas C, Franckenstein D, Schmidt M, et al. Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res 2010;12:R44.
27. Han SH, Jeon JH, Ju HR, et al. VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene 2003;22:4035-4046.
28. Junn E, Han SH, Im JY, et al. Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 2000;164:6287-6295.
29. Butler LM, Zhou X, Xu WS, et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 2002;99:11700-11705.
30. Jeon JH, Lee KN, Hwang CY, et al. Tumor suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1. Cancer Res 2005;65:4485-4489.
31. Shin D, Jeon JH, Jeong M, et al. VDUP1 mediates nuclear export of HIF1alpha via CRM1-dependent pathway. Biochim Biophys Acta 2008;1783:838-848.
32. Mobley JA, Brueggemeier RW. Estrogen receptormediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis 2004;25:3-9.
33. Mense SM, Remotti F, Bhan A, et al. Estrogen-induced breast cancer: alterations in breast morphology and oxidative stress as a function of estrogen exposure. Toxicol Appl Pharmacol 2008;232:78-85.